Zetiq Technologies and Biomics Biotechnologies Sign Collaboration Agreement
Collaboration agreement for the development and commercialization of screening and diagnosis technology of cervical cancer
Bio-Light announces the signing of a collaboration agreement between its subsidiary, Zetiq Technologies, and the Chinese company, Biomics Biotechnologies, whose expertise lies in the development and sales of medical and diagnostic products. This follows a memorandum of understanding signed between the two companies on 1st December 2009.
Collaboration between the two parties will take place in two stages: During the first stage Biomics Biotechnologies will be responsible for preparing for clinical trials and for the registration and regulatory approval process with the SFDA, the medical regulatory authority in China. According to the agreement, Zetiq will supply Biomics with an exclusive knowledge and patent license of the product in China, so as to enable Biomics to hold clinical trials and obtain registration and regulatory approval.
Upon successful completion of the regulatory approval, the second stage will ensue, whereby Biomics will be granted exclusive rights to market and distribute the product in China. The two sides have applied for funding of the collaboration by the Israel China Bi-national fund and received initial approval.
According to Dr. Adi Elkeles, CEO of Zetiq Technologies, "This collaboration agreement further demonstrates Zetiq's ability to commercialize its CellDetect technology."
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
In lab tests, new therapy slows spread of deadly brain tumor cells

Severity of enzyme deficiency central to favism

Why nerve cells die
5-HT_receptor
Saussurea
Identifying molecular targets for diabetes-related ED
Genetically engineered crops benefit many farmers, but the technology needs proper management to remain effective
Pramocaine
Genzyme Phase 3 Trial of Campath/Fludara Combination Shows Potential Benefit in Second-Line CLL

Dietary fibre powers the multivitamin factory in your gut - Luxembourg Institute of Health reveals critical link between fibre intake, gut bacteria, B vitamins and immune health
Tarceva helps patients with genetically distinct form of lung cancer live longer - Phase II study points to importance of EGFR biomarker to identify patients who can gain exceptional survival benefits
